Core Insights - Nektar Therapeutics announced that the FDA has granted Fast Track designation for rezpegaldesleukin, aimed at treating moderate-to-severe atopic dermatitis in patients aged 12 and older who do not respond adequately to topical therapies [1][3] Group 1: Product Development - Rezpegaldesleukin is an investigational biologic therapy that targets the interleukin-2 receptor complex to stimulate regulatory T cells (Tregs) [1][8] - The drug has shown rapid improvement in disease outcomes during a 12-week induction phase and sustained effects for at least 36 weeks post-treatment [2] - The Phase 2b REZOLVE-AD study has enrolled 398 patients and aims to assess the mean improvement in Eczema Area and Severity Index (EASI) score after a 16-week treatment period [4][5] Group 2: Clinical Trials - The REZOLVE-AD study began in October 2023, with patient enrollment across approximately 110 sites globally, including 67% in Europe and 17% in the United States [6] - The primary endpoint of the study is the mean improvement in EASI score, with secondary endpoints including the proportion of patients achieving specific assessment scores [5] - Enrollment criteria included a minimum EASI score of 16.0 and a minimum Body Surface Area (BSA) of 10% [7] Group 3: Market Potential - Atopic dermatitis affects around 30 million people in the United States, indicating a significant market opportunity for effective treatments [10] - The Fast Track designation allows for closer collaboration with the FDA, potentially expediting the development and approval process for rezpegaldesleukin [3]

Core Viewpoint - Nektar Therapeutics (NKTR) has experienced significant selling pressure, resulting in a 38.5% decline in stock price over the past four weeks, but analysts anticipate better earnings than previously expected, indicating potential for recovery [1]. Group 1: Stock Performance and Technical Indicators - NKTR's stock is currently in oversold territory, with an RSI reading of 28.23, suggesting that the heavy selling may be exhausting itself and a price reversal could occur soon [5]. - The Relative Strength Index (RSI) is a momentum oscillator that helps identify oversold conditions when the reading falls below 30, indicating potential entry opportunities for investors [2][3]. Group 2: Earnings Estimates and Analyst Sentiment - There has been a consensus among sell-side analysts to raise earnings estimates for NKTR, resulting in a 0.5% increase in the consensus EPS estimate over the last 30 days, which typically correlates with price appreciation [6]. - NKTR holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, further supporting the potential for a turnaround [7].

Core Viewpoint - Nektar Therapeutics (NKTR) has experienced a decline of 11.5% in its stock price over the past four weeks, but the formation of a hammer chart pattern suggests a potential trend reversal as buying interest may be emerging to counteract selling pressure [1][2]. Technical Analysis - The hammer chart pattern indicates a minor difference between opening and closing prices, with a long lower wick suggesting that the stock may have found support after a downtrend [3][4]. - This pattern typically signals that bears may have lost control, indicating a potential trend reversal when it occurs at the bottom of a downtrend [4]. Fundamental Analysis - There is rising optimism among Wall Street analysts regarding NKTR's future earnings, with a 0.1% increase in the consensus EPS estimate over the last 30 days, indicating agreement on the company's potential for better earnings [6][7]. - NKTR holds a Zacks Rank of 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks, which historically outperforms the market [8].

SAN FRANCISCO, Jan. 10, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the company has completed target enrollment in its REZOLVE-AD Phase 2b study of rezpegaldesleukin in patients with moderate-to-severe atopic dermatitis. Rezpegaldesleukin is a first-in-class interleukin-2 receptor (IL-2R) agonist that proliferates and activates regulatory T cells (Tregs) with promising dose-dependent clinical activity in multiple skin disease settings. Results from multiple clinical trials showed ...

When I wrote about Nektar Therapeutics (NASDAQ: NKTR ) in April, a major focus of discussion was rezpegaldesleukin and trials of the drug in atopic dermatitis and alopecia areata. Since those trials won't produce data until 2025, I rated the name aScientist and trader of biotech stock. Focus on trading around events such as trial results and NDA/BLA approvals. Also covering companies in industries regulated by the FDA. Articles present my opinion on stocks, but don't constitute investment advice.Analyst’s D ...

Nektar Therapeutics (NKTR) incurred a loss per share of 18 cents in the third quarter of 2024, narrower than the Zacks Consensus Estimate of a loss of 23 cents.In the year-ago quarter, the company reported an adjusted (excluding non-cash restructuring and impairment charges) loss of 18 cents.Total revenues remained flat year over year at $24.1 million. The reported figure beat the Zacks Consensus Estimate of $16 million.See the Zacks Earnings Calendar to stay ahead of market-making news. NKTR’s Q3 Results i ...

Financial Data and Key Metrics Changes - The company ended Q3 2024 with $249 million in cash and investments, with no debt on the balance sheet [46] - Revenue for Q3 2024 was $24.1 million, with full-year revenue expected to be between $90 million and $95 million [48] - The company anticipates ending 2024 with approximately $265 million in cash and investments, extending the cash runway into Q4 2026 [47][49] Business Line Data and Key Metrics Changes - The lead asset, rezpegaldesleukin (REZPEG), is advancing in Phase 2 studies for atopic dermatitis and alopecia areata, with enrollment on track [10][11] - The company is also advancing NKTR-165, a TNFR2 agonist antibody program, with IND submission planned for the second half of 2025 [13][34] - NKTR-255, an IL15 program in oncology, has shown promising data in enhancing CAR-T therapies and is being evaluated in multiple studies [16][41] Market Data and Key Metrics Changes - There are approximately 15 million people with moderate to severe atopic dermatitis in the USA, with less than 10% currently receiving biologics [9] - Nearly 7 million people in the U.S. are affected by alopecia areata, highlighting a significant unmet medical need for new therapies [11] Company Strategy and Development Direction - The company is focused on advancing its immunology and inflammation pipeline, particularly through REZPEG and NKTR-165 [7][13] - A strategic divestiture of the PEGylation reagent manufacturing facility aims to streamline operations and strengthen financial position [17][19] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential of REZPEG in treating atopic dermatitis and alopecia areata, citing promising early data [8][10] - The company is committed to advancing its pipeline and expects to provide updates on progress, particularly regarding upcoming data readouts in 2025 [82] Other Important Information - The company plans to recognize a gain of approximately $40 million to $45 million upon the sale of the Huntsville manufacturing facility [49] - R&D expenses for Q3 2024 were $35 million, with full-year R&D expenses expected to range between $120 million and $130 million [49] Q&A Session Summary Question: Can you quantify how close the studies for atopic dermatitis and alopecia areata are to completion? - Management indicated that enrollment is progressing well and will update the status on clinicaltrials.gov once completed [54] Question: What is the protocol regarding corticosteroid use in the Phase 2b atopic dermatitis trial? - Patients must wash out from topical corticosteroids before enrollment and are not permitted to use them during the study [59][60] Question: Can you provide details on the patient baseline characteristics in the REZPEG AD trial? - Management stated that the study is fully blinded, and detailed baseline characteristics will be provided in the top-line data [63] Question: What are the expected outcomes from the NKTR-255 studies? - Data presented showed significant improvements in lymphocyte counts and potential benefits in patients with severe lymphopenia [74][76] Question: After the 36-week maintenance period in the AD study, will patients continue treatment? - Patients will be followed for one year after treatment without further medication to assess remission effects [78]

Nektar Therapeutics (NKTR) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.19 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 21.74%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.21 per share when it actually produced a loss of $0.25, delivering a surprise of -19.05%.Over the last four quarters, t ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-24006 Title of each class Trading symbol(s) Name of each exchange on which registered Common Stock, $0.0001 par value ...

Exhibit 99.1 Nektar Therapeutics Reports Third Quarter 2024 Financial Results SAN FRANCISCO, November 7, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the third quarter ended September 30, 2024. Cash and investments in marketable securities on September 30, 2024 were $249.0 million as compared to $329.4 million at December 31, 2023. Nektar's cash and marketable securities are expected to support strategic development activities and operations into the fourth qu ...